Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants
- DOI
- Language of the publication
- English
- Date
- 2022-07-19
- Type
- Article
- Author(s)
- Parham, Kate A.
- Saeedian, Nasrin
- Ninkov, Marina
- Richer, Connor G.
- Li, Yue
- Wu, Kunyu
- Rashu, Rasheduzzaman
- Barr, Stephen D.
- Arts, Eric J.
- Haeryfar, S.M. Mansour
- Kang, C. Yong
- Troyer, Ryan M.
- Troyer, Ryan M.
- Publisher
- bioRxiv
Abstract
Recombinant vesicular stomatitis virus (rVSV) vaccines expressing Spike proteins of Wuhan, Beta and/or Delta variants of SARS-CoV-2 were generated and tested for induction of antibody and T cell immune responses in mice. rVSV-Wuhan and rVSV-Delta vaccines and a rVSV-Trivalent (mixed rVSV-Wuhan, -Beta, -Delta) vaccine elicited potent neutralizing antibodies (nAbs) against live SARS-CoV-2 Wuhan (USAWA1), Beta (B.1.351), Delta (B.1.617.2) and Omicron (B.1.1.529) viruses. Prime-boost vaccination with rVSV-Beta was less effective in this capacity. Heterologous boosting of rVSV-Wuhan with rVSV-Delta induced strong nAb responses against Delta and Omicron viruses, with rVSV-Trivalent vaccine consistently effective in inducing nAbs against all the SARS-CoV-2 variants tested. All vaccines, including rVSV-Beta, elicited a spike-specific immunodominant CD8+ T cell response. Collectively, rVSV vaccines targeting SARS-CoV-2 variants of concern may be considered in the global fight against COVID-19.
Subject
- Health,
- Coronavirus diseases,
- Immunization
Rights
Pagination
1-29
Peer review
No
Open access level
Green
Sponsors
Funding for this study was provided by CIHR of Canada and the Public Health Agency of Canada through a COVID-19 Immunity Taskforce grant (2020-VR2-173205) to RMT; a grant from CIHR (COV-440388) to SDB, RMT, EJA, SMMH, and CYK; a CoVaRR-Net Rapid Response Research Grant to SDB; and from Sumagen Canada to CYK.